RxDoctor Payments Data

Mark Varallo, MD

Psychiatry · Lockport, NYNPI 1881669281

Payments from drug & device makers

$1,972in general payments, 2019–2025

Across 89 payments — averaging $22.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$436
  • Alkermes, Inc.$394
  • Indivior Inc.$364
  • AbbVie$352
  • Otsuka America Pharmaceutical, Inc.$172
  • Johnson & Johnson$115
  • plus $138 from 3 others

What the payments were for

  • Food & beverage$1,972100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,972 in reported general payments places this provider in the 80th percentile of 3,713 psychiatry providers in New York.

See all psychiatry providers in New York

Medicare billing

Part B allowed, 2024
$15,828
Medicare patients
44
Services billed
173

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lurasidone Hcl46$25,833
VraylarCariprazine Hcl13$20,622
Clonazepam39$1,199
Thioridazine Hcl12$1,191
Buspirone Hcl66$973
Haloperidol Decanoate17$948
Oxcarbazepine38$701
Bupropion XlBupropion Hcl32$693
Quetiapine Fumarate64$637
Trazodone Hcl85$632
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine13$593
Escitalopram Oxalate70$562
Duloxetine Hcl20$440
Olanzapine35$438
Risperidone44$420

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$352$20,62213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,713 psychiatry providers in New York.

Other psychiatry in Lockport

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →